论文部分内容阅读
在第22届圣安东尼奥乳腺癌年会上,研究人员报告了一些癌治疗药的不良反应案例,旨在强调在寻找更新和更好的乳腺癌治疗药的同时,要同样关注它们的不良反应。 他莫西芬 肿瘤学家常久已来都知道,如果妇女是患ER(雌激素受体)阳性肿瘤,她们对激素治疗的应答会更佳。不管怎样,他莫西芬被认为是一种“安全的药物”,副作用少。即使是患ER阴性肿瘤的妇女也用以预防继发性癌和对骨的保护。此外,它对绝经期后妇女最有效,而对绝经期前的妇女料想亦无有害作用。然而,美国阿肯色医科大学的Hutchins教授对2691例行乳腺癌手术后接受化疗或化疗加5年他莫西芬治疗妇女的分析发现,接受他莫西芬治疗的ER阴性肿瘤患者其5年无病存活率明显低于那些不用他莫西芬的妇女(分别为82％对
At the 22nd Annual San Antonio Breast Cancer Symposium, researchers reported adverse events in some cancer treatments aimed at emphasizing the same concern about their side effects while looking for newer and better breast cancer remedies. It has long been known to all tamoxifen oncologists that women respond better to hormone therapy if they have ER (estrogen receptor) positive tumors. In any case, tamoxifen is considered a “safe drug” with few side effects. Even women with ER-negative tumors are used to prevent secondary cancers and bone protection. In addition, it is most effective for postmenopausal women and has no adverse effect on pre-menopausal women. However, Professor Hutchins from the University of Arkansas Medical Center analyzed 2691 women who underwent chemotherapy or chemotherapy plus 5 years of tamoxifen after breast cancer surgery and found that patients who received tamoxifen-treated ER-negative tumors had a 5-year disease-free history Survival rates were significantly lower for those who did not use tamoxifen (82% versus 82%, respectively)